WebFeb 27, 2024 · Pfizer Inc is in early-stage talks to acquire cancer drugmaker Seagen Inc in a potential multi-billion dollar deal, the Wall Street Journal reported, after advanced discussions between Merck and ... WebMar 13, 2024 · Pfizer Inc. signage is seen on July 22, 2024 in New York City. Jeenah Moon via Getty Images. Pfizer has agreed to buy Seattle-based Seagen for $43 billion in a blockbuster deal that would unite the pharmaceutical giant with a biotechnology company that pioneered a new type of tumor-killing medicine. The acquisition is the largest Pfizer …
Merck’s Stalled Seagen Deal Shows Valuing Cancer Drugs …
Merck has one of the premier oncology franchises in the industry and sells $17 billion of industry-leading cancer drug Keytruda. The drug is approved for at least 14 different types of cancer, and its sales just keep growing. Year-over-year revenue grew 26% in the second quarter. But Keytruda's patents expire in 2028, … See more Rumors have been circulating ever since The Wall Street Journalreported on the potential merger earlier in the summer. But the companies themselves have remained silent, even after the late July verdict in Seagen's lawsuit … See more Merck doesn't necessarily need to own Seagen in order to benefit from its technology. In fact, the two companies already have several ongoing collaborations. The … See more WebFeb 26, 2024 · Merck, which bought ADC-maker Imago BioSciences for $1.35 billion in November, is unlikely to show renewed interest in Seagen, analysts said. Merck was not immediately available for comment.... cews non arm\u0027s length employees
Merck in advanced talks to buy Seagen in nearly $40-billion deal
WebJul 8, 2024 · Drugmaker Merck & Co is in talks to buy cancer-focused biotech company Seagen Inc. According to reports, the deal could be worth roughly $40 billion or more. … WebJul 7, 2024 · Merck & Co is in advanced talks to buy Seagen in a deal that could value the cancer biotech at $40 billion or more, according to a report Wednesday. WebJun 17, 2024 · Merck is a massive player in the pharma space, with a valuation of more than $200 billion at the time of writing. As it happens, Seagen is no slouch, with a valuation around $30 as of today’s ... cews news today